Mesa Laboratories (NASDAQ:MLAB) Reaches New 12-Month High - What's Next?

Mesa Laboratories, Inc. (NASDAQ:MLAB - Get Free Report) reached a new 52-week high on Tuesday . The company traded as high as $125.30 and last traded at $124.32, with a volume of 148315 shares trading hands. The stock had previously closed at $124.76.

Analyst Ratings Changes

MLAB has been the subject of several analyst reports. Weiss Ratings raised Mesa Laboratories from a "sell (d)" rating to a "hold (c-)" rating in a report on Tuesday, August 11th. Wall Street Zen lowered Mesa Laboratories from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 15th. Finally, Wells Fargo & Company lifted their price target on Mesa Laboratories from $94.00 to $110.00 and gave the company an "equal weight" rating in a research report on Friday, August 14th. Three analysts have rated the stock with a Hold rating, According to MarketBeat.com, Mesa Laboratories currently has a consensus rating of "Hold" and a consensus price target of $110.00.

Mesa Laboratories Trading Down 0.4%

The company has a market cap of $696.19 million, a price-to-earnings ratio of 148.00 and a beta of 0.92. The company has a quick ratio of 1.32, a current ratio of 1.79 and a debt-to-equity ratio of 0.73. The company's 50-day moving average is $101.87 and its 200 day moving average is $97.61.

Mesa Laboratories (NASDAQ:MLAB - Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The medical instruments supplier reported $2.68 earnings per share for the quarter. The business had revenue of $60.14 million during the quarter. Mesa Laboratories had a net margin of 1.92% and a return on equity of 22.72%.

Mesa Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Monday, August 31st will be issued a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Monday, August 31st. Mesa Laboratories's dividend payout ratio (DPR) is presently 76.19%.

Insiders Place Their Bets

In other news, CAO Lyndsey Elizabeth Crennen sold 442 shares of the company's stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $89.50, for a total transaction of $39,559.00. Following the completion of the transaction, the chief accounting officer directly owned 2,020 shares of the company's stock, valued at $180,790. This represents a 17.95% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO John Sakys sold 2,827 shares of the stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $89.50, for a total value of $253,016.50. Following the transaction, the chief financial officer owned 19,785 shares in the company, valued at $1,770,757.50. This trade represents a 12.50% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 15,370 shares of company stock valued at $1,570,213. 2.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Mesa Laboratories

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. boosted its holdings in Mesa Laboratories by 5,366.7% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier's stock worth $26,000 after buying an additional 322 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of Mesa Laboratories in the fourth quarter valued at approximately $27,000. Kestra Advisory Services LLC acquired a new stake in shares of Mesa Laboratories in the fourth quarter worth approximately $55,000. BNP Paribas Financial Markets boosted its stake in shares of Mesa Laboratories by 30.9% in the third quarter. BNP Paribas Financial Markets now owns 1,029 shares of the medical instruments supplier's stock worth $69,000 after acquiring an additional 243 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in Mesa Laboratories by 432.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 842 shares of the medical instruments supplier's stock valued at $79,000 after purchasing an additional 684 shares in the last quarter. 90.60% of the stock is owned by hedge funds and other institutional investors.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc NASDAQ: MLAB is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company's product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source